The Korean Journal of Medicine

  • 제80권6호
  • /
  • Pages.680-686
  • /
  • 2011
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지

진행성 위암에 대한 1차 요법으로 Docetaxel, Cisplatin, 5-FU 복합화학요법의 효과와 안전성

Docetaxel, Cisplatin, 5-FU Combination Chemotherapy as a First-Line Treatment in Patients with Advanced Gastric Cancer

  • 김부경 (고신대학교 의과대학 내과학교실) ;
  • 박무인 (고신대학교 의과대학 내과학교실) ;
  • 박선자 (고신대학교 의과대학 내과학교실) ;
  • 김규종 (고신대학교 의과대학 내과학교실) ;
  • 문원 (고신대학교 의과대학 내과학교실) ;
  • 정수현 (고신대학교 의과대학 내과학교실) ;
  • 김혜수 (고신대학교 의과대학 내과학교실) ;
  • 남성진 (고신대학교 의과대학 내과학교실)
  • Kim, Bu-Kyung (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Park, Moo-In (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Park, Seun-Ja (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kim, Kyu-Jong (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Moon, Won (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Jeong, Su-Hyeon (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Kim, Hye-Soo (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Nam, Sung-Jin (Department of Internal Medicine, Kosin University College of Medicine)
  • 발행 : 2011.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 전이성 위암 환자들에서 1차 치료로서 투여된 docetaxel, cisplatin, 5-FU 복합화학요법의 효과와 안전성에 대하여 분석하였다. 방법: 2006년 4월부터 2009년 8월까지 조직학적으로 확진하고 절제가 불가능한 진행, 전이성 위암 환자 48명을 대상으로 의무기록을 통하여 후향적으로 조사하였다. 5-FU는 제1일부터 5일까지 750 mg/$m^2$으로 24시간 동안 지속적으로 정주하였고, 제2일째 docetaxel은 75 mg/$m^2$의 용량으로 1시간동안, cisplatin은 75 mg/$m^2$의 용량으로 1시간 30분 동안 정주하였고, 이상을 3주마다 반복하였다. 반응률은 2내지 3주기의 항암요법 시행 후 평가하였고, 부작용은 NCI CTC ver. 2.0을 기준으로 평가하였다. 결과: 총 48명의 환자들의 총 생존기간의 중앙값은 346일(235-457일)이었고 반응지속기간의 중앙값은 164일(149-179일)이었다. 총 48명의 환자 중 6명은 첫 반응률 평가 시행 전에 사망하거나 약제를 변경하거나 치료를 중단하여 치료반응 평가에서 제외되었다. 48명의 환자 중 완전 관해는 없었고 부분관해 27예(56%), 불변 10예(21%), 진행 5예(10%)로, 반응률은 56%였다. 전체 항암요법 292회 중 G3 이상의 빈혈 6회(2%), G4의 백혈구 감소증은 15회(5%), G4의 호중구 감소증은 154회(52.7%), G3 이상의 혈소판 감소증은 13회(4.4%)였다. 호중구 감소증에 의한 발열은 33회(11.3%)였고 작용으로 인한 용량감소는 165회(56.5%), 약제변경은 5회(1.7%)였으나 부작용으로 인한 사망은 없었다. 결론: Docetaxel, cisplatin, 5-FU의 복합화학요법은 수술을 할 수 없는 진행성 위암 환자들에 대한 1차 요법으로, 호중구감소증 등의 부작용의 빈도가 비교적 높으나 높은 반응률을 보이는 치료법이다. 부작용을 최소화하면서 반응률은 유지할 수 있는 가장 적절한 용량과 용법에 대한 합의를 도출해 낸다면 진행성 위암 환자들에 대한 1차 요법으로서의 그 가치는 더욱 높아질 것으로 생각한다.

Background/Aims: This study investigated the efficacy and safety of docetaxel/cisplatin/5-fluorouracil (DCF) combination chemotherapy as a first‐line treatment in patients with advanced gastric cancer. Methods: The study enrolled 48 patients diagnosed with unresectable pathologically proven gastric cancer who received DCF combination chemotherapy between April 2006 and August 2009. The dose administered was docetaxel 75 mg/$m^2$ for 1 h and cisplatin 75 mg/$m^2$ for 90 min on day 2, and 5-FU 750 mg/$m^2$ for 24 h on days 1-5, every 3 weeks. The response was assessed every three cycles. The toxicity was evaluated for every chemotherapy course according to the National Cancer Institute (NCI) toxicity criteria ver. 2.0. Results: The median age of the patients was 58 years (range 31-78 years). The median overall survival was 11.5 months (2.3-28.2 months) and the median time to progression was 5.5 months (0.3-18.9 months). No complete remission occurred. Of the patients, 56% achieved a partial response, 21% stable disease, and 10% progressive disease. The overall response rate was 56%. During a total 292 cycles, anemia worse than NCI toxicity grade 3 occurred in 2%, leukopenia in 33.1%, neutropenia in 67.1%, and thrombocytopenia in 4.4%. Neutropenic fever occurred in 33 cycles (11.3%), dose reduction due to side effects in 165 cycles (56.5%), and a regimen change due to side effect in five cycles (1.7%). Conclusions: Combination chemotherapy with docetaxel, cisplatin, and 5-FU is efficacious, but has relatively high toxicity. A DCF protocol that maximizes its efficiency, while minimizing toxicity, would be more useful as a first-line treatment in patients with advanced gastric cancer.

키워드

참고문헌

  1. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):ii41-ii44. https://doi.org/10.1093/annonc/mdg753
  2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  4. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8: 163-168. https://doi.org/10.1023/A:1008243606668
  5. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007;33:315-324. https://doi.org/10.1016/j.ctrv.2007.01.004
  6. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-386. https://doi.org/10.1016/0305-7372(93)90010-O
  7. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32A:226-230.
  8. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23: 5660-5667. https://doi.org/10.1200/JCO.2005.17.376
  9. Kang SH, Kim JI, Goh PG, et al. Docetaxel-Cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer. Korean J Gastroenterol 2007;50:157-163 discussion 207-209.
  10. Cocconi G, DeLisi V, di Blasio B. Randomizedcomparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982; 66:1263-1266.
  11. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer: North Central Cancer Treatmeht Group. J Clin Oncol 1994;12:412-416. https://doi.org/10.1200/JCO.1994.12.2.412
  12. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267. https://doi.org/10.1200/JCO.1997.15.1.261
  13. Vanhoefer U, Rougier P, Wilke H, et al. Final results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657. https://doi.org/10.1200/JCO.2000.18.14.2648
  14. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59. https://doi.org/10.1200/JCO.2003.04.130
  15. Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93. https://doi.org/10.1007/BF02993858
  16. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial: EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383. https://doi.org/10.1038/bjc.1994.310
  17. Taguchi T. An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Gan To Kagaku Ryoho 1994;21:2431-2437.
  18. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)- cisplatin (TC): an effective drug combination in gastric carcinoma: Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306. https://doi.org/10.1023/A:1008342013224
  19. Jeon SB, Ahn BM, Mun JH, et al. Docetaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Korean J Med 2005;68:672-677.
  20. Kim GJ, Lee SD, Park JW, et al. Efficacy and safety of combination chemotherapy with docetaxel and cisplatin as a first-line treatment for advanced gastric cancer. Korean J Med 2007;72:593-599.
  21. Roth AD, Maibach R, Falk S, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK): 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22:4020. https://doi.org/10.1200/JCO.2004.12.020
  22. Park SR, Chun JH, Kim YW, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 2005;28:433-438. https://doi.org/10.1097/01.coc.0000162424.69631.79
  23. Ozdemir NY, Abali H, Oksuzoglu B, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol 2010;27:680-684. https://doi.org/10.1007/s12032-009-9268-y